{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:04:32Z","timestamp":1780909472556,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UM1TR004538-01"],"award-info":[{"award-number":["1UM1TR004538-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although stimulant use disorder (StUD) is on the rise in the United States, few receive treatment. There are no FDA-approved medication treatments, despite evidence of clinical efficacy. Substance use treatment occurs within a complex landscape, with implementation of medication treatments requiring coordination among diverse partners and careful consideration of individual, organizational, and societal-level influences. The aim of this study was to identify partner- and theory-informed implementation strategies to support widespread adoption of medications for StUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven focus groups and four interviews were conducted with patients and providers in diverse substance use treatment settings (12 patients, 13 providers; 25 total participants). Rapid qualitative analysis was used to distill and compare findings across patient and provider samples, and findings were critically reviewed for alignment with the Expert Recommendations for Implementing Change taxonomy in accordance with recommendations for mapping implementation strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants highlighted multiple strategies that were categorized into three classes: capacity-building, integration, and implementation processes. Capacity-building strategies included training and education for providers and patients, families, and communities to reduce stigma, improve the patient-centeredness of care, and increase medication demand. Integration strategies focused mainly on organizational-level strategies such as mandating change, modifying record systems, and adding peers to care teams to enhance patient-centered care through required training, use of treatment plans, and preparing patients to be active participants in their treatment. Implementation processes strategies focused on the need for team meetings and internal\/external networking to reduce siloed work among care teams and improve communication with patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report on a model for incorporating patient and provider perspectives and considering multilevel contextual factors to design implementation strategies for feasibility and acceptability across diverse SUD treatment settings. Findings highlight the importance of patient-centered approaches to medication delivery, particularly for StUD, to increase treatment engagement and adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00678-y","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:15:01Z","timestamp":1779873301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stakeholder-informed recommendations for patient-centered medication service delivery for stimulant use disorder: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Enya B.","family":"Vroom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin P.","family":"Finley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Sharpe","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"4","key":"678_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2105\/AJPH.2025.308041","volume":"115","author":"SV Aronowitz","year":"2025","unstructured":"Aronowitz SV, Reed MK. The evolving overdose crisis: United States needs robust policy change to address the fourth wave. Am J Public Health. 2025;115(4):457\u20139. https:\/\/doi.org\/10.2105\/AJPH.2025.308041.","journal-title":"Am J Public Health"},{"issue":"4","key":"678_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2105\/AJPH.2022.307212","volume":"113","author":"RA Hoopsick","year":"2023","unstructured":"Hoopsick RA, Yockey RA. Methamphetamine-related mortality in the United States: co-involvement of heroin and fentanyl, 1999\u20132021. Am J Public Health. 2023;113(4):416\u20139. https:\/\/doi.org\/10.2105\/AJPH.2022.307212.","journal-title":"Am J Public Health"},{"key":"678_CR3","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:129733","volume-title":"Co-Involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants, 2011\u20132021","author":"MR Spencer","year":"2023","unstructured":"Spencer MR, Mini\u00f1o AM, Garnett MF. Co-Involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants, 2011\u20132021. Hyattsville, MD: National Center for Health Statistics; 2023. (NHCS Data Brief, no 474. https:\/\/doi.org\/10.15620\/cdc:129733."},{"key":"678_CR4","doi-asserted-by":"publisher","first-page":"107625","DOI":"10.1016\/j.ypmed.2023.107625","volume":"176","author":"RA Rawson","year":"2023","unstructured":"Rawson RA, Erath TG, Clark HW. The fourth wave of the overdose crisis: Examining the prominent role of psychomotor stimulants with and without fentanyl. Prev Med. 2023;176:107625. https:\/\/doi.org\/10.1016\/j.ypmed.2023.107625.","journal-title":"Prev Med"},{"key":"678_CR5","unstructured":"Substance abuse and mental health services administration. Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration., 2025 (HHS Publication No. PEP25-07-007, NSDUH Series H-60). https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national-report.pdf."},{"key":"678_CR6","unstructured":"Centers for disease control and prevention. Provisional drug overdose death counts. Hyattsville, MD: National Center for Health Statistics. 2025. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"678_CR7","doi-asserted-by":"publisher","unstructured":"Jones CM, Compton WM, Mustaquim D. (2020). Patterns and characteristics of methamphetamine use among adults \u2014 United States, 2015\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69:317\u2013323. https:\/\/doi.org\/10.15585\/mmwr.mm6912a1.","DOI":"10.15585\/mmwr.mm6912a1"},{"issue":"12","key":"678_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry. 2021;78(12):1329\u201342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2588.","journal-title":"JAMA Psychiatry"},{"key":"678_CR9","doi-asserted-by":"publisher","unstructured":"Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. (2020). Prescription psychostimulants for the treatment of stimulant use disorder: A systematic review and meta-analysis. Psychopharmacology. 2020;237(8):2233\u20132255. https:\/\/doi.org\/10.1007\/s00213-020-05563-3.","DOI":"10.1007\/s00213-020-05563-3"},{"issue":"6","key":"678_CR10","doi-asserted-by":"publisher","first-page":"e0234809","DOI":"10.1371\/journal.pone.0234809","volume":"15","author":"C Ronsley","year":"2020","unstructured":"Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, Wood E, Fairbairn N. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15(6):e0234809. https:\/\/doi.org\/10.1371\/journal.pone.0234809.","journal-title":"PLoS ONE"},{"issue":"3","key":"678_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","volume":"77","author":"PO Coffin","year":"2020","unstructured":"Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, Santos D, Colfax G, Batki SL. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020;77(3):246\u201355. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3655.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"678_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/ADM.0000000000000218","volume":"10","author":"LJ Mooney","year":"2016","unstructured":"Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. J Addict Med. 2016;10(4):236\u201343. https:\/\/doi.org\/10.1097\/ADM.0000000000000218.","journal-title":"J Addict Med"},{"issue":"2","key":"678_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, Ghitza UE, Wahle A, Kim M, Shores-Wilson K, Sparenborg S, Coffin P, Schmitz J, Wiest K, Bart G, Sonne SC, Wakhlu S, Rush AJ, Nunes EV, Shoptaw S. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2020214.","journal-title":"N Engl J Med"},{"key":"678_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/add.16529","author":"MJ Li","year":"2024","unstructured":"Li MJ, Chau B, Belin T, Carmody T, Jha MK, Marino EN, Trivedi M, Shoptaw SJ. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction. 2024. https:\/\/doi.org\/10.1111\/add.16529.","journal-title":"Addiction"},{"issue":"1 Suppl 1","key":"678_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000001299","volume":"18","author":"ASAM Members","year":"2024","unstructured":"Clinical Guideline Committee (CGC), Members ASAM, Team AAAP. Team, and the Institute for Research, Education and Training in Addictions (IRETA) Team. The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024;18(1 Suppl 1):1\u201356. https:\/\/doi.org\/10.1097\/ADM.0000000000001299.","journal-title":"J Addict Med"},{"issue":"2","key":"678_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1037\/adb0000830","volume":"37","author":"RL Brown","year":"2023","unstructured":"Brown RL, Batty E, Lofwall M, Kiviniemi M, Kizewski A. Opioid use-related stigma and health care decision-making. Psychol Addict Behav. 2023;37(2):222\u20137. https:\/\/doi.org\/10.1037\/adb0000830.","journal-title":"Psychol Addict Behav"},{"issue":"Suppl 2","key":"678_CR17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1370\/afm.2920","volume":"21","author":"H Klusaritz","year":"2023","unstructured":"Klusaritz H, Bilger A, Paterson E, Summers C, Barg FK, Cronholm PF, Saine ME, Sochalski J, Doubeni CA. Impact of stigma on clinician training for opioid use disorder care: a qualitative study in a primary care learning collaborative. Ann Fam Med. 2023;21(Suppl 2):S31\u20138. https:\/\/doi.org\/10.1370\/afm.2920.","journal-title":"Ann Fam Med"},{"key":"678_CR18","unstructured":"U.S. Department of Health and Human Services, Bethesda MD. 2022\u20132026 NIDA Strategic Plan. Natl Instit Health; 2025. https:\/\/nida.nih.gov\/about-nida\/2022-2026-strategic-plan\/priority-area-4."},{"issue":"10","key":"678_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/10826084.2021.1936051U","volume":"56","author":"TH Witte","year":"2021","unstructured":"Witte TH, Jaiswal J, Mumba MN, Mugoya GCT. Stigma surrounding the use of medically assisted treatment for opioid use disorder. Subst Use Misuse. 2021;56(10):1467\u201375. https:\/\/doi.org\/10.1080\/10826084.2021.1936051U.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"678_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3928\/02793695-20230215-03","volume":"61","author":"LL Davis","year":"2023","unstructured":"Davis LL. Are we witnessing a new wave of substance use disorders? A spotlight on stimulant use disorders. J Psychosoc Nurs Ment Health Serv. 2023;61(3):13\u20138. https:\/\/doi.org\/10.3928\/02793695-20230215-03.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"3","key":"678_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1017\/cts.2019.392","volume":"4","author":"AL Leppin","year":"2019","unstructured":"Leppin AL, Mahoney JE, Stevens KR, Bartels SJ, Baldwin LM, Dolor RJ, Proctor EK, Scholl L, Moore JB, Baumann AA, Rohweder CL, Luby J, Meissner P. Situating dissemination and implementation sciences within and across the translational research spectrum. J Clin Transl Sci. 2019;4(3):152\u20138. https:\/\/doi.org\/10.1017\/cts.2019.392.","journal-title":"J Clin Transl Sci"},{"key":"678_CR22","doi-asserted-by":"publisher","unstructured":"McGovern MP, Garneau HC, Gotham HJ, Rossi FS. What is necessary for implementation science to actually improve the state of addiction treatment and research? J Subst Use Addict Treat. 2025;209753. https:\/\/doi.org\/10.1016\/j.josat.2025.209753.","DOI":"10.1016\/j.josat.2025.209753"},{"key":"678_CR23","unstructured":"Vroom EB, Finley EP, Deem Bolton C, Karns-Wright T, Sharpe Potter J. Patient and provider demand for and readiness to adopt medications for stimulant use disorders in real-world settings: pre-planning toward accelerated implementation. Drug Alcohol Rev. Under review."},{"key":"678_CR24","doi-asserted-by":"publisher","first-page":"111409","DOI":"10.1016\/j.drugalcdep.2024.111409","volume":"262","author":"SL Calcaterra","year":"2024","unstructured":"Calcaterra SL, Yamkovoy K, Aytha Swathi P, Ciccarone D, del Pozo B, Englander H, Wang J, Barocas JA. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015\u20132019. Drug Alcohol Depend. 2024;262:111409. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111409.","journal-title":"Drug Alcohol Depend"},{"key":"678_CR25","doi-asserted-by":"publisher","unstructured":"Okafor CN, Carmody T, Stotts AL, Bart G, Mayes TL, Karns-Wright T, Trivedi M, Shoptaw S, Potter JS. Sociodemographic and patient reported outcomes by racial and ethnicity status among participants in a randomized controlled trial for methamphetamine use disorder. Drug Alcohol Depend Rep. https:\/\/doi.org\/10.1016\/j.dadr.2024.100230","DOI":"10.1016\/j.dadr.2024.100230"},{"key":"678_CR26","doi-asserted-by":"publisher","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, Schechter MT, Oviedo-Joekes E. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(37). https:\/\/doi.org\/10.1186\/s13011-019-0227-0.","DOI":"10.1186\/s13011-019-0227-0"},{"issue":"2","key":"678_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/08897077.2019.1671940","volume":"41","author":"EL Davis","year":"2019","unstructured":"Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, Adams S. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: a systematic literature review. Subst Abuse. 2019;41(2):216\u201331. https:\/\/doi.org\/10.1080\/08897077.2019.1671940.","journal-title":"Subst Abuse"},{"key":"678_CR28","doi-asserted-by":"publisher","unstructured":"Lynch AC, Weber AN, Hedden S, Sabbagh S, Arndt S, Acion L. Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA. Subst Abuse Treat Prev Policy. 2021;16(8). https:\/\/doi.org\/10.1186\/s13011-021-00342-5.","DOI":"10.1186\/s13011-021-00342-5"},{"key":"678_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11414-023-09866-z","volume":"51","author":"EB Matthews","year":"2024","unstructured":"Matthews EB, Peral M. Using collaborative documentation to support person-centered care in substance use settings. J Behav Health Serv Res. 2024;51:74\u201389. https:\/\/doi.org\/10.1007\/s11414-023-09866-z.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"678_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mcna.2021.08.010","volume":"106","author":"D Ciccarone","year":"2022","unstructured":"Ciccarone D, Shoptaw S. Understanding stimulant use and use disorders in a new era. Med Clin North Am. 2022;106(1):81\u201397. https:\/\/doi.org\/10.1016\/j.mcna.2021.08.010.","journal-title":"Med Clin North Am"},{"issue":"1","key":"678_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14688","volume":"1508","author":"CM Jones","year":"2022","unstructured":"Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Ann N Y Acad Sci. 2022;1508(1):3\u201322. https:\/\/doi.org\/10.1111\/nyas.14688.","journal-title":"Ann N Y Acad Sci"},{"key":"678_CR32","doi-asserted-by":"publisher","unstructured":"Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019;14. https:\/\/doi.org\/10.1186\/s13012-019-0861-y.","DOI":"10.1186\/s13012-019-0861-y"},{"key":"678_CR33","doi-asserted-by":"publisher","unstructured":"Woodward EN, Singh RS, Ndebele-Ngwenya P, Melgar Castillo A, Dickson KS, Kirchner JE. A more practical guide to incorporating health equity domains in implementation determinant frameworks. Implement Sci Commun. 2021;2. https:\/\/doi.org\/10.1186\/s13012-019-0861-y.","DOI":"10.1186\/s13012-019-0861-y"},{"key":"678_CR34","doi-asserted-by":"publisher","unstructured":"Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, Proctor EK, Kirchner JE. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10. https:\/\/doi.org\/10.1186\/s13012-015-0209-1.","DOI":"10.1186\/s13012-015-0209-1"},{"issue":"1","key":"678_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1525822X16639015","volume":"29","author":"G Guest","year":"2016","unstructured":"Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2016;29(1):3\u201322. https:\/\/doi.org\/10.1177\/1525822X16639015.","journal-title":"Field Methods"},{"key":"678_CR36","doi-asserted-by":"publisher","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523. https:\/\/doi.org\/10.1016\/j.socscimed.2021.114523.","journal-title":"Soc Sci Med"},{"key":"678_CR37","volume-title":"Personal health inventory","author":"U.S. Department of Veterans Affairs","year":"2022","unstructured":"U.S. Department of Veterans Affairs. Personal health inventory. Washington, DC: U.S. Department of Veterans Affairs; 2022. https:\/\/www.va.gov\/WHOLEHEALTH\/docs\/PHI_Jan2022_Final_508.pdf."},{"key":"678_CR38","unstructured":"Maietta R, Hamilton A. Designing and executing qualitative data collection projects [training presentation]. 15th Annual Qualitative Research Summer Intensive; July 2018; Chapel Hill, NC."},{"key":"678_CR39","doi-asserted-by":"publisher","unstructured":"Kowalski CP, Nevedal AL, Finley EP, Young JP, Lewinski AA, Midboe AM, Hamilton AB. Planning for and assessing rigor in rapid qualitative analysis (PARRQA): a consensus-based framework for designing, conducting, and reporting. Implement Sci. 2024;19. https:\/\/doi.org\/10.1186\/s13012-024-01397-1.","DOI":"10.1186\/s13012-024-01397-1"},{"key":"678_CR40","doi-asserted-by":"publisher","unstructured":"Gale RC, Wu J, Erhardt T, Bounthavong M, Reardon CM, Damschroder LJ, Midboe AM. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019;14. https:\/\/doi.org\/10.1186\/s13012-019-0853-y.","DOI":"10.1186\/s13012-019-0853-y"},{"key":"678_CR41","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.1016\/j.psychres.2019.112516","volume":"280","author":"AB Hamilton","year":"2019","unstructured":"Hamilton AB, Finley EP. Qualitative methods in implementation research: an introduction. Psychiatry Res. 2019;280:112516. https:\/\/doi.org\/10.1016\/j.psychres.2019.112516.","journal-title":"Psychiatry Res"},{"key":"678_CR42","doi-asserted-by":"publisher","unstructured":"Nevedal AL, Reardon CM, Opra Widerquist MA, Jackson GL, Cutrona SL, White BS, Damschroder LJ. Rapid versus traditional qualitative analysis using the Consolidated Framework for Implementation Research (CFIR). Implement Sci. 2021;16. https:\/\/doi.org\/10.1186\/s13012-021-01111-5.","DOI":"10.1186\/s13012-021-01111-5"},{"issue":"2","key":"678_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11414-015-9475-6","volume":"44","author":"BJ Powell","year":"2017","unstructured":"Powell BJ, Beidas RS, Lewis CC, Aarons GA, McMillen JC, Proctor EK, Mandell DS. Methods to improve the selection and tailoring of implementation strategies. J Behav Health Serv Res. 2017;44(2):177\u201394. https:\/\/doi.org\/10.1007\/s11414-015-9475-6.","journal-title":"J Behav Health Serv Res"},{"key":"678_CR44","doi-asserted-by":"publisher","unstructured":"Waltz TJ, Powell BJ, Fern\u00e1ndez ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implement Sci. 2019;14. https:\/\/doi.org\/10.1186\/s13012-019-0892-4.","DOI":"10.1186\/s13012-019-0892-4"},{"key":"678_CR45","doi-asserted-by":"publisher","unstructured":"Leeman J, Rohweder C, Lafata JE, Wangen M, Ferrari R, Shea CM, Brenner A, Roth I, Fleming O, Toles M. A streamlined approach to classifying and tailoring implementation strategies: recommendations to speed the translation of research to practice. Implement Sci Commun. 2024;5. https:\/\/doi.org\/10.1186\/s43058-024-00606-8.","DOI":"10.1186\/s43058-024-00606-8"},{"key":"678_CR46","doi-asserted-by":"publisher","unstructured":"Lott A, Danner AN, Malte CA, Salameh HA, Bachowski D, Gordon AJ, Hagedorn HJ, Frost MC, Williams EC, Saxon AJ, Trim RS, Hawkins EJ. Implementing buprenorphine for opioid use disorder in Veterans Health Administration primary care: a qualitative analysis. Addict Sci Clin Pract. 2025;20(1). https:\/\/doi.org\/10.1186\/s13722-025-00568-9.","DOI":"10.1186\/s13722-025-00568-9"},{"key":"678_CR47","doi-asserted-by":"publisher","unstructured":"Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024;19(1). https:\/\/doi.org\/10.1186\/s13722-024-00440-2.","DOI":"10.1186\/s13722-024-00440-2"},{"key":"678_CR48","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.drugalcdep.2022.109394","volume":"234","author":"E Pivovarova","year":"2022","unstructured":"Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: a qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022;234:109394. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109394.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"678_CR49","doi-asserted-by":"publisher","first-page":"e2236904","DOI":"10.1001\/jamanetworkopen.2022.36904","volume":"5","author":"EJ Edelman","year":"2022","unstructured":"Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of implementation facilitation to promote adoption of medications for addiction treatment in US HIV clinics: a randomized clinical trial. JAMA Netw Open. 2022;5(10):e2236904. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36904.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"678_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s43058-022-00306-1","volume":"3","author":"H Cheng","year":"2022","unstructured":"Cheng H, McGovern MP, Garneau HC, Hurley B, Fisher T, Copeland M, Almirall D. Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes. Implement Sci Commun. 2022;3(1):72. https:\/\/doi.org\/10.1186\/s43058-022-00306-1.","journal-title":"Implement Sci Commun"},{"key":"678_CR51","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.drugpo.2024.104567","volume":"132","author":"LM Harris","year":"2024","unstructured":"Harris LM, Guerrero EG, Khachikian T, Serrett V, Marsh JC. Expert providers implement integrated and coordinated care in opioid use disorder treatment. Int J Drug Policy. 2024;132:104567. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104567.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"678_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.annemergmed.2022.09.025","volume":"81","author":"ES Anderson","year":"2023","unstructured":"Anderson ES, Rusoja E, Luftig J, Ullal M, Shardha R, Schwimmer H, Friedman A, Hailozian C, Herring AA. Effectiveness of substance use navigation for emergency department patients with substance use disorders: an implementation study. Ann Emerg Med. 2023;81(3):297\u2013308. https:\/\/doi.org\/10.1016\/j.annemergmed.2022.09.025.","journal-title":"Ann Emerg Med"},{"issue":"8","key":"678_CR53","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/add.16751","volume":"120","author":"E Day","year":"2025","unstructured":"Day E, Pechey LC, Roscoe S, Kelly JF. Recovery support services as part of the continuum of care for alcohol or drug use disorders. Addiction. 2025;120(8):1497\u2013520. https:\/\/doi.org\/10.1111\/add.16751.","journal-title":"Addiction"},{"key":"678_CR54","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3389\/fpsyg.2019.01052","volume":"10","author":"D Eddie","year":"2019","unstructured":"Eddie D, Hoffman L, Vilsaint C, Abry A, Bergman B, Hoeppner B, Weinstein C, Kelly JF. Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching. Front Psychol. 2019;10:1052. https:\/\/doi.org\/10.3389\/fpsyg.2019.01052.","journal-title":"Front Psychol"},{"issue":"1","key":"678_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13722-024-00528-9","volume":"19","author":"AW Kang","year":"2024","unstructured":"Kang AW, Bailey A, Surace A, Stein L, Rohsenow D, Martin RA. Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders. Addict Sci Clin Pract. 2024;19(1):95. https:\/\/doi.org\/10.1186\/s13722-024-00528-9.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"678_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/08897077.2021.1931633","volume":"43","author":"JB Anderson","year":"2022","unstructured":"Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, Jenkins P. Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes. Subst Abuse. 2022;43(1):222\u201330. https:\/\/doi.org\/10.1080\/08897077.2021.1931633.","journal-title":"Subst Abuse"},{"issue":"12","key":"678_CR57","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3390\/healthcare10122393","volume":"10","author":"E Johnson","year":"2022","unstructured":"Johnson E, Bolshakova M, Vosooghi A, Lam CN, Trotzky-Sirr R, Bluthenthal R, Schneberk T. Effect of didactic training on barriers and biases to treatment of opioid use disorder: meeting the ongoing needs of patients with opioid use disorder in the emergency department during the COVID-19 pandemic. Healthcare. 2022;10(12):2393. https:\/\/doi.org\/10.3390\/healthcare10122393.","journal-title":"Healthcare"},{"key":"678_CR58","doi-asserted-by":"publisher","first-page":"108688","DOI":"10.1016\/j.jsat.2021.108688","volume":"137","author":"JS Potter","year":"2022","unstructured":"Potter JS, Finley EP, King VL, Lanham HJ, Schmidt S, Schneegans S, Rosen KD. Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: implementing GetWaiveredTX. J Subst Abuse Treat. 2022;137:108688. https:\/\/doi.org\/10.1016\/j.jsat.2021.108688.","journal-title":"J Subst Abuse Treat"},{"key":"678_CR59","doi-asserted-by":"publisher","unstructured":"Davis A, Knudsen HK, Walker DM, Chassler D, Lunze K, Westgate PM, Oga E, Rodriguez S, Tan S, Holloway J, Walsh SL, Oser CB, Lefebvre RC, Fanucchi LC, Glasgow L, McAlearney AS, Surratt HL, Konstan MW, Huang TT, LeBaron P, \u2026 Huerta TR. Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial. Lancet Reg Health Am. 2024;32:100710. https:\/\/doi.org\/10.1016\/j.lana.2024.100710.","DOI":"10.1016\/j.lana.2024.100710."},{"key":"678_CR60","doi-asserted-by":"publisher","unstructured":"Whipple CR, Kaynak \u00d6, Kruis NE, Silesky MD, Bonnevie E, Smyser J, \u2026 Kensinger WS.Challenging public stigma: the impact of a statewide social media campaign to reduce opioid use disorder stigma. Drugs Educ Prev Policy. 2024;1\u201310. https:\/\/doi.org\/10.1080\/09687637.2024.2416583.","DOI":"10.1080\/09687637.2024.2416583."},{"key":"678_CR61","doi-asserted-by":"publisher","first-page":"104543","DOI":"10.1016\/j.drugpo.2024.104543","volume":"132","author":"A Holland","year":"2024","unstructured":"Holland A, Freeman TP, Nicholls J, Burke C, Howkins J, Harris M, Hickman M, Attwood A, Carlisle V, Krykant P, Maynard OM. Making sense of drug use and dependence\u2013a scoping review of mass media interventions intended to reduce stigma towards people who use drugs. Int J Drug Policy. 2024;132:104543. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104543.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"678_CR62","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/00178969231197623","volume":"82","author":"E Bonnevie","year":"2023","unstructured":"Bonnevie E, Silesky MD, Goldbarg J, Gudmundsen C, Fields M, Smyser J. A multi-site intervention using influencers to communicate about syringe service programmes. Health Educ J. 2023;82(7):779\u201391. https:\/\/doi.org\/10.1177\/00178969231197623.","journal-title":"Health Educ J"},{"key":"678_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2025.2540947","author":"M Leibensperger","year":"2025","unstructured":"Leibensperger M, Dunn Silesky M, Gudmundsen C, Bonnevie E. Exploring the impact of an influencer-led program on community support for harm reduction in West Virginia: a preliminary evaluation. Subst Use Misuse. 2025. https:\/\/doi.org\/10.1080\/10826084.2025.2540947.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"678_CR64","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1186\/s12913-023-10217-z","volume":"23","author":"SE Clingan","year":"2023","unstructured":"Clingan SE, D\u2019Ambrosio BM, Davidson PJ. Patient brokering in for-profit substance use disorder treatment: a qualitative study with people with opioid use disorder and professionals in the field. BMC Health Serv Res. 2023;23(1):1214. https:\/\/doi.org\/10.1186\/s12913-023-10217-z.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"678_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-019-0134-8","volume":"14","author":"EC Williams","year":"2019","unstructured":"Williams EC, Matson TE, Harris AHS. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addict Sci Clin Pract. 2019;14(1):6. https:\/\/doi.org\/10.1186\/s13722-019-0134-8.","journal-title":"Addict Sci Clin Pract"},{"key":"678_CR66","doi-asserted-by":"publisher","DOI":"10.1037\/ser0000966","author":"BP O\u2019Rourke","year":"2025","unstructured":"O\u2019Rourke BP, Hogan TH, Miller A, Fried M, Williams M, Teater J, Kauffman E, Clark AD, Hall OT, Huynh P, Hefner JL. The System-Wide Medication for Opioid Use Disorder (SW-MOUD) program: a description of program implementation. Psychol Serv. 2025. https:\/\/doi.org\/10.1037\/ser0000966.","journal-title":"Psychol Serv"},{"key":"678_CR67","volume-title":"Research design: qualitative, quantitative, and mixed methods approaches","author":"JW Creswell","year":"2017","unstructured":"Creswell JW, Creswell JD. Research design: qualitative, quantitative, and mixed methods approaches. 4th ed. Thousand Oaks, CA: Sage; 2017.","edition":"4"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00678-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:25:18Z","timestamp":1780907118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00678-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00678-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were in accordance with the ethical standards of the institutional review boards and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent was not required. Approval was obtained from the Institutional Review Board at the University of Texas Health Science Center at San Antonio (20220766HU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}